
Medication Delivery: The Next Frontier for The Vaping Industry?
Update (October 2026): This is a 2016 news post, kept as dated news with factual corrections. It's written for adults; if you don't smoke or vape, don't start.
Vaping has become increasingly common, so it was only a matter of time before people looked at uses beyond nicotine and quitting smoking.
We’ve all heard about the use of cannabis and CBD, and I recently discussed one of the latest alternatives, vaping caffeine.
Researchers are also looking at whether inhaled, vapor-style delivery can work for prescription medications, with mixed success.
Inhaled medication is nothing new. Asthma inhalers have been used for decades to deliver medicine as a fine mist or dry powder that relaxes constricted airways. They don't heat or vaporize anything, though, which is how e-cigarettes work.
When this was written, some states with medical cannabis programs allowed vaporized oils and concentrates but not smoking the plant itself.
Vaping’s success in smoking cessation has prompted some pharmaceutical companies to look at similar heat-based inhalation to deliver medications.
Inhaled drugs reach the bloodstream quickly through the lungs, which could help people who need fast relief.
The Evidence for Vapable Medications
Medical cannabis offers one example. A 2014 Israeli study gave eight patients with chronic nerve pain a single dose from a metered-dose cannabis inhaler.
Pain intensity dropped by an average of 45% within 20 minutes and returned to baseline within 90 minutes. It was a small, early study without a placebo group.
Results like this are why researchers are interested in fast-acting inhaled delivery for other conditions, though each drug has to be proven safe and effective on its own.
There are at least two efforts out there to produce vapable medications. One from Alexza Pharmaceuticals aims to deliver anti-seizure medication to patients with epilepsy and other seizure disorders.
Early study results at the time showed promise in fighting seizures caused by photosensitivity, as well as effectiveness in preventing further seizures when administered after the patient suffered a seizure event.
Inhaled drugs haven’t been a sure-fire hit, though. Diabetes patients might seem like ideal candidates, since many need daily insulin injections, but sales of the inhaled insulin Afrezza were weak.
Sanofi, which marketed Afrezza, dropped it after its launch fell short. The drug’s creator, MannKind, still plans to press on though, and MannKind still sells Afrezza today. Afrezza is a dry powder inhaler, not a vaporizer.
The Vape Misinformation Fight
One issue these companies may face is public confusion about vaping. Negative news about nicotine vaping may make patients wary of other inhaled products too.
The evidence is more nuanced than either side often admits. There have been numerous studies on e-cigarette aerosol, and the National Academies found substantial evidence that exposure to toxic substances other than nicotine is significantly lower from e-cigarettes than from cigarettes. Lower is not the same as safe.
Unregulated products can also cause real harm. CDC found that vitamin E acetate, an additive in some THC-containing vaping products, was strongly linked to the 2019 outbreak of lung injuries known as EVALI. Never vape THC products from informal or illicit sources.
Any vaped medication would need to meet the same standards as other drugs. Until then, the main proven role for nicotine e-cigarettes is helping adult smokers switch away from cigarettes.
Sources
- The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler, Journal of Pain & Palliative Care Pharmacotherapy (via Europe PMC)
- Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products, Centers for Disease Control and Prevention
- Public Health Consequences of E-Cigarettes: Conclusions by Level of Evidence, National Academies of Sciences, Engineering, and Medicine
- Afrezza, MannKind Corporation


